
Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer
For patients with breast cancer receiving treatment with PI3K or AKT inhibitors such as capivasertib (Truqap) or alpelisib (Piqray), Hope S. Rugo, MD, FASCO, recommends pretreating patients for rash. In an interview with Oncology Nursing News at the 24th …